Current research progress in targeted anti-angiogenesis therapy for osteosarcoma.

Area of Science:

• Oncology
• Molecular Biology
• Biomedical Research

Background:

• Osteosarcoma (OS) is the most common primary bone cancer, predominantly affecting adolescents.
• Current survival rates for OS have plateaued despite advances in chemotherapy.
• Angiogenesis, the formation of new blood vessels, is vital for tumor progression and metastasis in OS.

Purpose of the Study:

• To review preclinical and developmental research on targeted anti-angiogenic therapies for osteosarcoma.
• To highlight the limitations and challenges associated with these targeted therapies in OS treatment.

Main Methods:

• Review of existing literature on targeted anti-angiogenic agents in osteosarcoma.
• Analysis of therapies including anti-VEGF monoclonal antibodies, tyrosine kinase inhibitors, and endostatin.

Main Results:

• Targeted anti-angiogenic therapies represent a potential adjunct to conventional osteosarcoma treatments.
• Several agents like bevacizumab, sorafenib, apatinib, pazopanib, regorafenib, and endostar have been investigated.
• Clinical efficacy and safety data for these targeted therapies in osteosarcoma are still limited.

Conclusions:

• Targeted anti-angiogenic therapy holds potential for improving osteosarcoma patient outcomes.
• Further comprehensive research is required to establish the definitive safety and efficacy of these therapies.
• Understanding the role of angiogenesis in the bone microenvironment is crucial for optimizing treatment strategies.